INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 346 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $757,774 | -9.5% | 23,965 | +16.8% | 0.00% | 0.0% |
| Q2 2023 | $837,009 | +13.4% | 20,525 | +3.6% | 0.00% | 0.0% |
| Q1 2023 | $738,096 | +6.7% | 19,804 | -0.2% | 0.00% | 0.0% |
| Q4 2022 | $692,043 | -33.4% | 19,835 | +6.7% | 0.00% | 0.0% |
| Q3 2022 | $1,039,000 | +14.4% | 18,582 | +5.9% | 0.00% | 0.0% |
| Q2 2022 | $908,000 | -51.3% | 17,547 | -31.6% | 0.00% | 0.0% |
| Q1 2022 | $1,865,000 | -44.4% | 25,670 | -9.5% | 0.00% | -50.0% |
| Q4 2021 | $3,355,000 | -79.4% | 28,375 | -76.6% | 0.00% | -81.8% |
| Q3 2021 | $16,289,000 | -12.2% | 121,428 | +6.0% | 0.01% | -8.3% |
| Q2 2021 | $18,556,000 | +825.5% | 114,605 | +358.8% | 0.01% | +1100.0% |
| Q1 2021 | $2,005,000 | +48.5% | 24,981 | +0.6% | 0.00% | 0.0% |
| Q4 2020 | $1,350,000 | +516.4% | 24,824 | +137.8% | 0.00% | – |
| Q2 2020 | $219,000 | – | 10,437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |